June 20, 2019
Vaxart to Present at ASM Microbe 2019
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
June 20, 2019
Cyxone starts in-human testing of its multiple sclerosis drug candidate
Swedish biotech company focused on autoimmune diseases, Cyxone is testing its drug candidate T20K, its first-in-human, phase I, clinical trial, for the treatment of multiple sclerosis (MS).
June 20, 2019
AstraZeneca’s Bevespi Aerosphere approved in Japan for COPD patients
AstraZeneca’s Bevespi Aerosphere has been approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease, becoming the first approved fixed-dose, long-acting dual bronchodilator in a pressurised metered-dose inhaler device in Japan.
June 20, 2019
Verastem Oncology Announces Leadership Changes
Robert Forrester Stepping Down From His Roles as President and Chief Executive Officer Chief Operating Officer, Dan Paterson Appointed President…
June 20, 2019
Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directors
HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the…
June 20, 2019
Merck Hosts 2019 Investor Day
-$MRK #MRK–At a meeting with the investment community today, Merck (NYSE: MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term.
June 20, 2019
PureTech Establishes New Corporate Headquarters in Boston’s Seaport District
PureTech will continue to leverage leadership in Brain-Immune-Gut axis biology to develop novel categories of therapeutics
June 20, 2019
Psoriasis Market and Forecast Analysis to 2025 – Otezla’s Favorable Safety Profile and Lower Cost Compared to Leading Anti-TNFs will Continue to Drive its Uptake
DUBLIN–(BUSINESS WIRE)–The “Psoriasis Market and Forecast Analysis to 2025” drug pipelines has been added to ResearchAndMarkets.com’s offering. Psoriasis is a…
June 20, 2019
Teva launches generic version of Tracleer tablets in the United States
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today
announced the launch of a generic version of Tracleer®1
(bosentan) tablets, 62.5 mg and 125 mg, in the U.S.
June 20, 2019
Zymeworks Announces Pricing of $175.0 Million Public Offering
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics (the “Company”), announced today the pricing of…